Your session is about to expire
← Back to Search
LB-100 for Glioblastoma
Study Summary
This trial is testing if a new drug, LB100, can pass into the brain. People with brain tumors who are scheduled for surgery are eligible. The trial involves getting the drug during surgery and having follow-up appointments.
- Glioblastoma
- Astrocytoma
- Oligodendroglioma
- Brain Tumor
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 7 Patients • NCT03027388Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are we still able to enroll people in this test?
"That is correct. The clinical trial in question, which was first advertised on 1/9/2019, is still looking for enrollees. So far, 25 patients have been recruited from a single site."
What is the mortality rate for people who use LB-100?
"Since this is a Phase 2 trial, there is some data supporting LB-100's safety but none yet for its efficacy. Therefore, we gave it a score of 2."
Are there similar precedents for LB-100's use?
"Currently, there are two clinical trials underway for LB-100; neither of which have reached Phase 3. Although the majority of testing for this treatment is taking place in Duarte, California - as that is where the company headquarters are located - there are two other research sites."
How many patients are enrolled in this research project?
"That is correct. The clinical trial, which began recruitment on 1/9/2019, is still looking for 25 individuals from a single site."
Share this study with friends
Copy Link
Messenger